



**JUN - 6 2005**

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Mr. L.G. Chandrasekhar  
Managing Director  
Sutures India Private Limited  
472 D, 13<sup>th</sup> Cross, 4<sup>th</sup> Phase  
Peenya Industrial Area,  
Bangalore 560058, India

Re: K041515

Trade/Device Name: TRUGLYDE Absorbable Polyglycolic Acid Surgical Suture  
Regulation Number: 21 CFR 878.4493  
Regulation Name: Absorbable Poly(glycolide/L-lactide) Surgical Suture  
Regulatory Class: II  
Product Code: GAM  
Dated: March 17, 2005  
Received: March 21, 2005

Dear Mr. Chandrasekhar:

This letter corrects our substantially equivalent letter of April 8, 2005 regarding the trade name.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have **determined** the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 – Mr. L.G. Chandrasekhar

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "M. Provost", is written over a horizontal line.

Miriam C. Provost, Ph.D.  
Acting Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known): K041515

Device Name: TRUGLYDE Absorbable Polyglycolic Acid Surgical Suture

### Indications For Use:

TRUGLYDE Absorbable Polyglycolic Acid Surgical Suture is indicated for use in soft tissue approximation, including use in ophthalmic surgery, but not for use in cardiovascular and neurological procedures

Prescription Use   x  

AND/OR

Over-The-Counter Use


(Part 21 CFR 801 Subpart D)

(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)



(Signature)  
Division of General, Restorative  
Neurological Devices

510(k) Number: K041515

APR 8 2005

SUTURES INDIA PVT.LTD
SUBMISSION OF PREMARKET NOTIFICATION (510K) FOR ABSORBABLE POLYGLYCOLIC ACID SUTURE

SECTION NO: 17

PAGE NO: -17-1

K041515

510K SUMMARY as required by: 21CFR 807.92

**A. APPLICANT INFORMATION**

Name : SUTURES INDIA PVT. LTD

Address : 472 D 13 th Cross, 4 th Phase,  
Peenya Industrial Area,  
Bangalore-560058. India

PHONE NO. : 91-80-51272102 / 51272103 / 51272104

FAX NO. : 91-80-51171056

E mail : [sutures@vsnl.com](mailto:sutures@vsnl.com)

Web Address : [www.suturesin.com](http://www.suturesin.com)

B. Contact Person : L.G.Chandrasekhar

: MANAGING DIRECTOR

C. Date Prepared : May 15,2004

**D. DEVICE TRADE NAME**

- Trade Name : TRUGLYDE
- Common name : Absorbable Surgical Suture,Synthetic (Polyglycolic Acid)
- Classification Name: Absorbable (poly glycolic acid) suture

**E. PREDICATE DEVICES**

- Maxon Absorbable Polyglycolic acid Suture, 510(k) Number K990951, United States Surgical Corporation, Norwalk, CT 06856
- Surgisorb PGA absorbable suture, 510(k) Number K984374. Samyang Corporation , Seoul, Korea.